The Novo Nordisk Foundation (NNF) is funding a major new R&D initiative in the area of respiratory infections, with up to DKK 1.8 billion ($260 million) earmarked for the project. The NNF – a ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

These are also known as biosolutions. This is the aim of the new initiative at the Technical University of Denmark (DTU): Novo Nordisk Foundation Biotechnology Research Institute for the Green ...